Skip to main content

Table 4 Variables associated with a teicoplanin initial trough concentration (Cmin) ≥ 20 μg/mL: univariate and multivariate analyses

From: Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

Factors

No of patients with teicoplanin initial Cmin ≥20 μg/mL (%)

Univariate analysis

Multivariate analysis

Patients with factor

Patients without factor

Crude odds ratio (95%CI)

P-value

Adjusted odds ratio (95%CI)

P-value

Enhanced high loading dose regimen

117/149 (78.5%)

150/363 (41.3%)

5.19 (3.33–8.089)

< 0.001

7.75 (4.62–12.99)

< 0.001

Sex (male)

161/318 (50.6%)

106/194 (54.6%)

0.85 (0.60–1.22)

0.378

  

Age (> 65 years)

162/318 (50.9%)

105/194 (54.1%)

0.88 (0.62–1.26)

0.485

  

Body mass index< 18.5

59/124 (47.6%)

208/388 (53.6%)

0.79 (0.52–1.18)

0.242

  

Body mass index ≥25

47/74 (63.5%)

220/438 (50.2%)

1.73 (1.04–2.87)

0.034

2.33 (1.24–4.38)

0.008

eGFR≥60 mL/min/1.73 m2

164/293 (56.0%)

103/219 (47.0%)

1.43 (1.01–2.04)

0.045

1.15 (0.68–1.95)

0.603

Heart disease

111/208 (53.4%)

156/304 (51.3%)

1.09 (0.76–1.55)

0.648

  

Chronic renal failure

47/116 (40.5%)

220/396 (55.6%)

0.55 (0.36–0.83)

0.004

0.62 (0.38–1.03)

0.062

Diabetes mellitus

58/112 (51.8%)

209/400 (52.3%)

0.98 (0.65–1.49)

0.931

  

Collagen disease

25/53 (47.2%)

242/459 (52.7%)

0.80 (0.45–1.42)

0.443

  

Chronic respiratory disease

14/27 (51.9%)

253/485 (52.2%)

0.99 (0.46–2.15)

0.975

  

Inflammatory bowel disease

44/89 (49.4%)

223/423 (52.7%)

0.88 (0.56–1.39)

0.573

  

Intensive care unit stay (> 3 days)

34/98 (34.7%)

233/414 (56.3%)

0.41 (0.26–0.65)

< 0.001

0.32 (0.19–0.56)

< 0.001

Liver cirrhosis/chronic hepatic dysfunction

34/72 (47.2%)

233/440 (53.0%)

0.80 (0.48–1.31)

0.367

  

Malignant tumor

99/204 (48.5%)

168/308 (54.5%)

0.79 (0.55–1.12)

0.182

  

Total parenteral nutrition

45/102 (44.1%)

222/410 (54.1%)

0.70 (0.43–1.03)

0.070

0.54 (0.32–0.92)

0.022

Serum albumin < 2.5 g/dL (median)

79/217 (36.4%)

188/295 (63.7%)

0.33 (0.23–0.47)

< 0.001

0.24 (0.15–0.37)

< 0.001

Ventilator use

37/90 (41.1%)

230/422 (54.5%)

0.58 (0.37–0.93)

0.021

1.51 (0.68–3.36)

0.316

Surgery within 28 days

68/158 (43.0%)

199/354 (56.2%)

0.59 (0.40–0.86)

0.006

0.47 (0.30–0.74)

0.001

Transplantation

6/8 (75.0%)

261/504 (51.8%)

2.79 (0.56–13.97)

0.289

  

Steroid use

42/85 (49.4%)

225/427 (52.7%)

0.88 (0.55–1.40)

0.580

  

Immunosuppressive therapy

18/28 (64.3%)

249/484 (51.4%)

1.70 (0.77–3.76)

0.186

  

Anticancer therapy

26/47 (55.3%)

241/465 (51.8%)

1.15 (0.63–2.10)

0.648

  

MRSA infections

72/139 (51.8%)

195/373 (52.3%)

0.98 (0.66–1.45)

0.923

  

Complicated MRSA infections

54/99 (54.5%)

213/413 (51.6%)

1.13 (0.73–1.75)

0.595

  

APACHE II score ≥ 15

54/130 (41.5%)

213/382 (55.8%)

0.56 (0.38–0.84)

0.005

0.78 (0.44–1.35)

0.371

  1. eGFR, estimated glomerular filtration rate, APACHE II Acute physiology and chronic health evaluation II score